Literature DB >> 19657467

Carbocyclic 4'-Epiformycin.

Jian Zhou1, Minmin Yang, Akin Akdag, Haisheng Wang, Stewart W Schneller.   

Abstract

Formycin is a naturally occurring biologically responsive C-nucleoside. In pursuing the design and syntheses of novel C-nucleosides, convenient access to carbocyclic C-nucleosides based on the formycin framework was a goal. One such target was carbocyclic 4'-epiformycin (4). This compound is reported via a procedure based on an asymmetric aldol/ring closure methathesis strategy. To provide a preliminary glimpse into the biological characterization of 4 an antiviral assay was conducted. Target 4 was found to be inactive and to lack cytotoxicity to the host cells.

Entities:  

Year:  2008        PMID: 19657467      PMCID: PMC2720546          DOI: 10.1016/j.tet.2007.10.054

Source DB:  PubMed          Journal:  Tetrahedron        ISSN: 0040-4020            Impact factor:   2.457


  20 in total

1.  Antiviral activity of cyclopentenyl nucleosides against orthopox viruses (Smallpox, monkeypox and cowpox).

Authors:  C K Chu; Y H Jin; R O Baker; J Huggins
Journal:  Bioorg Med Chem Lett       Date:  2003-01-06       Impact factor: 2.823

2.  Imidazolinium salts as catalysts for the ring-opening alkylation of meso epoxides by alkylaluminum complexes.

Authors:  H Zhou; E J Campbell; S T Nguyen
Journal:  Org Lett       Date:  2001-07-12       Impact factor: 6.005

3.  R3Al-R'3SiOTf: novel and powerful reagent system for stereospecific alkylation-silylation reactions of epoxides.

Authors:  Ponnusamy Shanmugam; Masaaki Miyashita
Journal:  Org Lett       Date:  2003-09-04       Impact factor: 6.005

Review 4.  S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents.

Authors:  E De Clercq
Journal:  Biochem Pharmacol       Date:  1987-08-15       Impact factor: 5.858

5.  The enantiomers of carbocyclic 5'-norguanosine: activity towards Epstein-Barr virus.

Authors:  Vasanthakumar Rajappan; Stewart W Schneller; Stephanie L Williams; Earl R Kern
Journal:  Bioorg Med Chem       Date:  2002-04       Impact factor: 3.641

Review 6.  Carbocyclic nucleosides (carbanucleosides) as new therapeutic leads.

Authors:  Stewart W Schneller
Journal:  Curr Top Med Chem       Date:  2002-10       Impact factor: 3.295

7.  2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.

Authors:  J A Secrist; A T Shortnacy; J A Montgomery
Journal:  J Med Chem       Date:  1985-11       Impact factor: 7.446

8.  Adenosine kinase inhibitors. 3. Synthesis, SAR, and antiinflammatory activity of a series of l-lyxofuranosyl nucleosides.

Authors:  Bheemarao G Ugarkar; Angelo J Castellino; Jay S DaRe; Michele Ramirez-Weinhouse; Joseph J Kopcho; Sanna Rosengren; Mark D Erion
Journal:  J Med Chem       Date:  2003-10-23       Impact factor: 7.446

9.  In vitro processing of the adenosine analog formycin A to the mono-, di-, and triphosphate by a soluble multienzyme system from mouse liver.

Authors:  F J Dye; E F Rossomando
Journal:  Biosci Rep       Date:  1982-04       Impact factor: 3.840

10.  8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.

Authors:  Gary B Evans; Richard H Furneaux; Graeme J Gainsford; John C Hanson; Gregory A Kicska; Antony A Sauve; Vern L Schramm; Peter C Tyler
Journal:  J Med Chem       Date:  2003-01-02       Impact factor: 7.446

View more
  2 in total

1.  Consecutive three-component synthesis of 3-(hetero)aryl-1H-pyrazoles with propynal diethylacetal as a three-carbon building block.

Authors:  Lucilla Levi; Christina Boersch; Charlotte F Gers; Eugen Merkul; Thomas J J Müller
Journal:  Molecules       Date:  2011-11-07       Impact factor: 4.411

2.  Synthetic, Structural, and Anticancer Activity Evaluation Studies on Novel Pyrazolylnucleosides.

Authors:  Yogesh Yadav; Deepti Sharma; Kumar Kaushik; Vineet Kumar; Amitabh Jha; Ashok K Prasad; Christophe Len; Sanjay V Malhotra; Jesper Wengel; Virinder S Parmar
Journal:  Molecules       Date:  2019-10-30       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.